Skip to main content

Table 2 Effect of long-term (10 weeks) empagliflozin treatment on body weight, tibia length, visceral fat weight, subcutaneous fat weight, liver weight, and left ventricular weight of SHRcp

From: Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome

  Control (n = 12) SGLT2 (n = 12)
Body weight (g) 733.3 ± 5.3 664.0 ± 9.2*
Tibia length (mm) 39.1 ± 0.1 39.0 ± 0.1
Epididymal fat weight (g) 6.4 ± 0.2 7.0 ± 0.3
Mesenteric fat weight (g) 12.3 ± 0.2 11.8 ± 0.2
Perirenal fat weight (g) 56.2 ± 1.0 53.8 ± 1.3
Subcutaneous fat weight (g) 69.0 ± 1.5 52.7 ± 2.2*
Liver weight (g) 29.5 ± 0.74 28.6 ± 0.35
Left ventricular weight (mg) 1465 ± 44 1363 ± 16#
  1. Control SHRcp fed control diet; SGLT2 SHRcp fed control diet containing empagliflozin. Values are mean ± SEM. Statistical analysis was performed by unpaired Student’s t test
  2. # P < 0.05, * P < 0.01 versus control